NASDAQ:ALLO
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$149.6M, and the diluted share count rose 13.2%.Summary generated from Allogene Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−53.4%
Debt / equityn/a
Free cash flow−$149.6M
FCF marginn/a
Share count change+13.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 114 | 0 | 0 | 0 | 0 |
| Operating income | −180 | −336 | −328 | −273 | −209 |
| Net income | −182 | −340 | −327 | −258 | −191 |
| Free cash flow | −206 | −226 | −239 | −201 | −150 |
Recent filings
- 8-KDirector or officer change
Sep 2, 2026 - 4Insider transaction report
Aug 25, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 4Insider transaction report
Jul 6, 2026 - 8-KResults of a shareholder vote
Jun 22, 2026 - 8-KDirector or officer change
May 28, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026